Dr. Joshua E. Lowentritt, MD

Dr. Lowentritt practices at Nola Dialysis in Metairie, Louisiana.

Dr. Lowentritt's NPI, 1235180266, was assigned on May 15, 2006. Dr. Lowentritt graduated from Tulane University School of Medicine in 1996. Dr. Lowentritt holds Louisiana license 023415.

Dr. Lowentritt's primary practice is Nola Dialysis, at 4409 Utica Ave, Metairie, LA 70006 in Jefferson Parish. The practice phone is (504) 248-2137.

Dr. Lowentritt's primary practice is Nola Dialysis in Metairie, Louisiana. Dr. Lowentritt is also affiliated with East Jefferson General Hospital. The medical group on file is Crescent City Physicians, Inc. Dmand AI also links Dr. Lowentritt to 1 more hospital, 2 dialysis centers, 2 group practices and clinics, 1 home health agency and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Lowentritt practices, 7 sites in all. Vendor and product names are available with a free account.

Nephrology is Dr. Lowentritt's primary specialty in the NPI Registry, under taxonomy code 207RN0300X. Dr. Lowentritt is licensed in Louisiana.

CMS data shows 725 Medicare services from Dr. Lowentritt across 8 procedure codes in 2024, for 191 Medicare patients. Medicare paid $70,865 for them.

CMS counts 191 Medicare patients who saw Dr. Lowentritt in 2024. The largest group is 65 to 74, with 71 patients. 75% of them have chronic kidney disease, and 75% have high blood pressure. 15% are also on Medicaid. Their average risk score is 2.38, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Lowentritt's median patient age at 71, with 52% women.

In 2024, Dr. Lowentritt wrote 5,025 Medicare Part D claims for 470 patients. 80% of them were for generic drugs. CMS names the drug for 4,357 of them, across 93 drugs with 11 or more claims each, at $614,196 in total drug cost. In 2023, CMS named 5,790 claims across 114 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 76 out of 100 for Dr. Lowentritt for performance year 2024, reported as part of a group. Dr. Lowentritt accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Lowentritt as offering telehealth.

CMS Open Payments shows 256 general payments to Dr. Lowentritt from 34 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 65% of the total. Fresenius USA Marketing, Inc. paid the most, $3,901.

Dr. Lowentritt graduated from Tulane University School of Medicine in 1996.